CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes

Area of Science:

• Molecular Oncology
• Epigenetics
• DNA Repair Mechanisms

Background:

• The NuRD component CHD4 (Chromodomain Helicase DNA Binding Protein 4) is implicated in cancer development.
• Tumor suppressor gene (TSG) silencing is a critical mechanism in colorectal cancer progression.
• DNA damage repair pathways can be co-opted for oncogenic functions.

Purpose of the Study:

• To define the oncogenic role of CHD4 in initiating and maintaining tumor suppressor gene silencing in colorectal cancer.
• To investigate the mechanisms by which CHD4 is recruited to sites of DNA damage and influences gene expression.
• To evaluate the therapeutic potential of targeting CHD4 in colorectal cancer treatment.

Main Methods:

• Investigated CHD4 recruitment to DNA damage sites, including oxidative damage (8-hydroxydeoxyguanosine, 8-OHdG) and double-strand breaks.
• Utilized CHD4 knockdown experiments to assess the impact on TSG expression and colorectal cancer cell phenotypes.
• Correlated CHD4 and 8-OHdG levels with TSG expression and clinical outcomes in patient cohorts.

Main Results:

• CHD4 recruits repressive chromatin proteins and DNA methyltransferases to impose de novo DNA methylation at TSGs.
• CHD4 retention maintains DNA hypermethylation and transcriptional silencing of TSGs.
• CHD4 knockdown reactivates silenced TSGs, suppressing colorectal cancer cell proliferation, invasion, and metastasis.
• High CHD4 and 8-OHdG levels, coupled with low TSG expression, correlate with early recurrence and reduced survival.

Conclusions:

• CHD4 plays a critical oncogenic role in colorectal cancer by epigenetically silencing tumor suppressor genes.
• Targeting CHD4 or its associated pathways presents a promising therapeutic strategy for colorectal cancer.
• CHD4 and 8-OHdG levels serve as potential biomarkers for predicting disease recurrence and patient survival.